Detection, Evaluation and Monitoring of Frailties in the Elderly (FRAGING)
NCT ID: NCT04992286
Last Updated: 2023-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
800 participants
INTERVENTIONAL
2021-09-07
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypothesis is that conducting a fragility screening in a rural area (Mauriac health (Mauriac health basin) and a semi-urban area (Vichy health basin) would allow an effective would allow an effective allocation of expenses. In more detail, the costs are direct medical, direct non-medical, indirect and intangible costs, and efficiency is measured by measured by the quality of life score (LEIPAD). The hypothesis is that the early detection of people's frailties and their management improves their quality of life
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determinant of the Risk of the Becoming Frail in the Non-dependent Elederly
NCT04012840
Identification of Frailty Predictors of Adverse Health Outcomes in Community-dwelling Individuals Aged 50 and Over
NCT04603144
Validation of a Frailty Self Assessment Tool
NCT04085432
Determining the Needs of Aging People With Disabilities
NCT02735005
Education for Prevention and Treatment of Frailty
NCT05610605
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
people aged 65 years or more
men or women, age Superior to 65 years
questionnaire
questionnaire to evaluate fragility
accelerometer
To evaluate physical activity level
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
questionnaire
questionnaire to evaluate fragility
accelerometer
To evaluate physical activity level
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Living in the Mauriac or Vichy health basin.
* Able to give informed consent to participate in the research.
* Affiliation to a Social Security system.
Exclusion Criteria
* Persons under guardianship or curatorship.
* Refusal to participate in the study expressed by the person.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université d'Auvergne
OTHER
Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques
OTHER
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martine Duclos
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A00367-34
Identifier Type: OTHER
Identifier Source: secondary_id
RBHP 2021 DUCLOS 2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.